Oral vs injectable GLP-1s: how the options compare in 2026
Two oral GLP-1 pills now sit alongside the weekly injectables, and the Medicare Bridge covers both. Here is how the formats actually differ.
For most of the GLP-1 era, the medication meant a weekly injection. That has changed. Two oral GLP-1 options arrived within months of each other, and the new Medicare GLP-1 Bridge covers both pills and injectables. If you are weighing your options, here is how the formats actually differ.
The injectables
The injectable GLP-1s, Wegovy (semaglutide) and Zepbound (tirzepatide), are taken as a once-weekly shot under the skin. They have the longest track record, and in trials tirzepatide has produced the largest average weight loss of the current options. The trade-off is the weekly injection itself, along with rotating injection sites and storing the medication properly.
The oral options
There are now two daily pills, and they are not the same. Oral Wegovy, an oral form of semaglutide, was approved in December 2025. Because it is a peptide, it has specific timing rules: it is taken in the morning on an empty stomach, at least 30 minutes before any food or drink other than water. In a late-stage trial it produced roughly 16.6% average weight loss. Foundayo (orforglipron), approved on April 1, 2026, is a different kind of molecule. As a once-daily small-molecule pill, it can be taken any time of day with no food or water restrictions, which makes it the most flexible to fit into a routine. In trials it produced about 12.4% average weight loss at the highest dose.
How to think about the trade-offs
There is no single best option. If injections are a barrier, a daily pill removes that hurdle. A weekly shot is one event per week, the Wegovy pill needs a consistent morning routine, and Foundayo is the most forgiving on timing. In trials, tirzepatide and the oral semaglutide pill have shown higher average weight loss than orforglipron, though individual results vary widely. Under the Medicare Bridge, the covered list includes Wegovy (injectable and oral), the Zepbound KwikPen, and Foundayo. Which medication and which dose are decisions for you and your prescribing clinician. The numbers here are trial averages, not a ranking of what is right for any one person.
What stays the same
Whichever format you choose, the fundamentals do not change. Appetite drops, so protein and hydration matter. Side effects tend to follow a predictable rhythm. And the clearest picture of how treatment is going comes from tracking the trend over weeks, not reacting to single days.
How Titra helps
Titra works the same way whether your medication is a weekly shot or a daily pill. It logs each dose, tracks side effects against your cycle, keeps your protein and weight trends in view, and turns it all into a summary you can share with your clinician. This article is for general information and is not medical advice. Medication and dose decisions belong with your clinician.